Department of Anatomy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Doctoral Program in Medical Sciences, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Iran Biomed J. 2021 Nov 1;25(6):417-25. doi: 10.52547/ibj.25.6.417.
Hyperuricemia induces nephropathy through the mediation of oxidative stress, tubular injury, inflammation, and fibrosis. The high uric acid level is associated with the reduction of vitamin D levels. However, the reno-protective effects of this vitamin in hyperuricemia condition remain unknown. This study aimed to elucidate calcitriol treatment in a uric acid-induced hyperuricemia mice model.
: Uric acid (125 mg/kg body weight [BW]) was administered intraperitoneally for 7 (UA7) and 14 (UA14) days. Calcitriol (0.5 g/kg BW) was intraperitoneally injected for the following seven days, after 14 days of uric acid induction (UA14VD7 group). The control group received NaCl 0.9%, by the same route. Serum creatinine was measured using calorimetric method, and uric acid levels were assessed using enzymatic calorimetric assay. Tubular injury and fibrosis were assessed using PAS and Sirius red staining. RT-PCR and real-time reverse transcription PCR were carried out for the analyses of SOD-1, Collagen-1, and TGF-1 mRNA expression in the kidney. Immunostaining of super oxide dismutase type 1 (SOD-1) was performed to detect its expression in the kidney.
Uric acid and creatinine levels markedly increased in UA14 groups, followed by an exacerbation of tubular injury. RT-PCR revealed the upregulation of Collagen-1 and TGF-1, along with the downregulation of SOD-1. Calcitriol treatment attenuated the injury with reducing uric acid and creatinine levels, as well as tubular injury. This was associated with lower Collagen-1 and TGF-1 mRNA expression compared to the UA7 and UA14 groups. SOD-1 was upregulated in epithelial cells in the UA14VD7 group.
Calcitriol treatment after uric acid induction may attenuate kidney injury through upregulation of SOD-1 and downregulation of Collagen-1 and TGF-1 gene expression.
高尿酸血症通过氧化应激、肾小管损伤、炎症和纤维化介导诱导肾病。高水平的尿酸与维生素 D 水平降低有关。然而,这种维生素在高尿酸血症中的肾保护作用尚不清楚。本研究旨在阐明在尿酸诱导的高尿酸血症小鼠模型中使用骨化三醇治疗。
尿酸(125mg/kg 体重[BW])腹膜内给药 7(UA7)和 14(UA14)天。在尿酸诱导 14 天后(UA14VD7 组),腹膜内注射骨化三醇(0.5μg/kg BW),持续七天。对照组通过相同途径给予生理盐水 0.9%。使用比色法测量血清肌酐,使用酶比色法评估尿酸水平。使用 PAS 和 Sirius 红染色评估肾小管损伤和纤维化。进行 RT-PCR 和实时逆转录 PCR 分析肾脏中 SOD-1、Collagen-1 和 TGF-1mRNA 的表达。通过免疫染色检测肾脏中超氧化物歧化酶 1(SOD-1)的表达。
UA14 组尿酸和肌酐水平明显升高,随后肾小管损伤加重。RT-PCR 显示 Collagen-1 和 TGF-1 上调,同时 SOD-1 下调。骨化三醇治疗通过降低尿酸和肌酐水平以及肾小管损伤来减轻损伤。与 UA7 和 UA14 组相比,这与 Collagen-1 和 TGF-1mRNA 表达降低有关。UA14VD7 组上皮细胞中 SOD-1 上调。
尿酸诱导后使用骨化三醇治疗可能通过上调 SOD-1 和下调 Collagen-1 和 TGF-1 基因表达来减轻肾脏损伤。